Promising Results Unveiled from Immunic’s Phase 2 Clinical Trials for Multiple Sclerosis Therapy

Immunic, Inc. (NASDAQ:IMUX) unveils promising results from phase 2 clinical trials at the ACTRIMS Forum 2024, showing potential for vidofludimus calcium as a therapy for progressive multiple sclerosis and its impact on fatigue possibly linked to Epstein-Barr virus reactivation. The interim analysis revealed a substantial reduction in serum neurofilament light chain levels in PMS patients treated with vidofludimus calcium, indicating potential neuroprotective benefits. The drug also showed promise in preventing EBV reactivation and alleviating fatigue in MS patients. These groundbreaking results mark a significant stride in Immunic’s clinical pipeline.